 |
36 Diseases |  |
5 Trials |
|
5 Trials |  |
637 News |  |
| «12345678910» |
- | Olysio (simeprevir) / J&J, Medivir
Trial completion, Combination therapy: Simeprevir in Combination With Sofosbuvir in Treatment-Na (clinicaltrials.gov) - Feb 24, 2016
P2, N=30, Completed, Sponsor: Peter J. Ruane, M.D.
Recruiting --> Completed
- |||| Olysio (simeprevir) / J&J, Medivir
Trial completion, HEOR: A Study to Examine Patient Characteristics, Health Care Management and Health Outcomes of Hepatitis C Virus (HCV) Patients Treated With Simeprevir (clinicaltrials.gov) - Feb 22, 2016
P4, N=315, Completed, Sponsor: Janssen Scientific Affairs, LLC
Recruiting --> Completed Active, not recruiting --> Completed
- Olysio (simeprevir) / J&J, Medivir, Tivicay (dolutegravir) / ViiV Healthcare
Enrollment open, Trial initiation date, Trial primary completion date: Drug Interaction Potential Between Dolutegravir and Simeprevir in HIV/HCV Seronegative Volunteers (clinicaltrials.gov) - Feb 4, 2016
P=N/A, N=25, Recruiting, Sponsor: University of Colorado, Denver
Active, not recruiting --> Completed Not yet recruiting --> Recruiting | Initiation date: Oct 2015 --> Feb 2016 | Trial primary completion date: Dec 2015 --> Oct 2016
- |||| Enrollment open, Trial primary completion date: A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of the Combination of AL-335, Odalasvir, and Simeprevir (clinicaltrials.gov) - Feb 1, 2016
P2, N=60, Recruiting, Sponsor: Alios Biopharma Inc.
Not yet recruiting --> Recruiting | Initiation date: Oct 2015 --> Feb 2016 | Trial primary completion date: Dec 2015 --> Oct 2016 Not yet recruiting --> Recruiting | Trial primary completion date: Feb 2016 --> Jun 2016
- | Trial completion: A Study to Evaluate the Effect of ACH-3102 and Simeprevir on AL-335 Pharmacokinetics in Healthy Volunteers (clinicaltrials.gov) - Jan 29, 2016
P1, N=32, Completed, Sponsor: Alios Biopharma Inc.
Not yet recruiting --> Recruiting | Trial primary completion date: Feb 2016 --> Jun 2016 Recruiting --> Completed
- | Olysio (simeprevir) / J&J, Medivir
Enrollment closed, Trial primary completion date: SMV + SOF With/Without RBV for IFN-II Patients With CHC (clinicaltrials.gov) - Jan 26, 2016
P4, N=40, Active, not recruiting, Sponsor: SC Liver Research Consortium, LLC
Recruiting --> Completed Recruiting --> Active, not recruiting | Trial primary completion date: Nov 2016 --> Jun 2016
- | Olysio (simeprevir) / J&J, Medivir
Trial completion: An Efficacy and Safety Study of Simeprevir and Sofosbuvir With and Without Ribavirin in Participants With Recurrent Genotype 1 Hepatitis C Post-Orthotopic Liver Transplant (clinicaltrials.gov) - Jan 25, 2016
P2, N=46, Completed, Sponsor: Janssen Scientific Affairs, LLC
Recruiting --> Active, not recruiting | Trial primary completion date: Nov 2016 --> Jun 2016 Active, not recruiting --> Completed
- || Olysio (simeprevir) / J&J, Medivir
Trial completion, Combination therapy: Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Subjects With Chronic Genotype 4 Hepatitis C Virus Infection (clinicaltrials.gov) - Jan 21, 2016
P3, N=40, Completed, Sponsor: Janssen R&D Ireland
Active, not recruiting --> Completed Active, not recruiting --> Completed
- |||| Olysio (simeprevir) / J&J, Medivir
Trial completion: 3-year Follow-up Study in Patients Previously Treated With TMC435-Containing Regimen for the Treatment of Hepatitis C Virus Infection (clinicaltrials.gov) - Jan 20, 2016
P2b, N=249, Completed, Sponsor: Janssen R&D Ireland
Active, not recruiting --> Completed Active, not recruiting --> Completed
- |||| Olysio (simeprevir) / J&J, Medivir
Trial completion, Combination therapy: An Efficacy and Safety Study of a 8 or 12-Week Treatment Regimen of Simeprevir in Combination With Sofosbuvir in Treatment-Naive and Experienced Participants With Chronic Genotype 4 Hepatitis C Virus Infection (clinicaltrials.gov) - Dec 29, 2015
P2, N=63, Completed, Sponsor: Janssen-Cilag International NV
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Olysio (simeprevir) / J&J, Medivir
New P4 trial, Combination therapy: Randomized Clinical Trial of Sofosbuvir in Combination With Daclatasvir or Simeprevir for 12 Weeks in Non-cirrhotic Subjects Infected With Chronic Hepatitis C Virus Genotype 1 (TNT) (clinicaltrials.gov) - Dec 9, 2015
P4, N=394, Recruiting, Sponsor: Federal University of S
- Olysio (simeprevir) / J&J, Medivir
Trial primary completion date: SMV + SOF With/Without RBV for IFN-II Patients With CHC (clinicaltrials.gov) - Nov 30, 2015
P4, N=40, Recruiting, Sponsor: SC Liver Research Consortium, LLC
Active, not recruiting --> Completed Trial primary completion date: Jun 2016 --> Nov 2016
- Enrollment change, Trial primary completion date: Real-life Security and Efficacy of DAA-based Therapy in HCV/HIV-Coinfected Patients (clinicaltrials.gov) - Nov 15, 2015
P=N/A, N=1000, Recruiting, Sponsor: Valme University Hospital
Trial primary completion date: Jun 2016 --> Nov 2016 N=230 --> 1000 | Trial primary completion date: Dec 2015 --> Dec 2017
- Enrollment change: GEHEP: Efficacy and Safety of Therapy Against HCV Based on Direct-acting Antivirals in Real-life Conditions (clinicaltrials.gov) - Nov 14, 2015
P=N/A, N=1000, Recruiting, Sponsor: Valme University Hospital
N=230 --> 1000 | Trial primary completion date: Dec 2015 --> Dec 2017 N=210 --> 1000
- | Pegasys (pegylated interferon ? -2a) / Roche, Sunvepra (asunaprevir) / BMS, Olysio (simeprevir) / J&J, Medivir
New P2 trial: SWITCH-1: Switching Regimen in Treating Cirrhotic HCV GT1b Subjects (clinicaltrials.gov) - Oct 22, 2015
P2, N=160, Recruiting, Sponsor: Humanity & Healthy GI and Liver Centre
- | Olysio (simeprevir) / J&J, Medivir
Enrollment closed: An Efficacy, Safety and Pharmacokinetics Study of Simeprevir, Daclatasvir and Sofosbuvir in Participants With Chronic Hepatitis C Virus Genotype 1 or 4 Infection and Decompensated Liver Disease (clinicaltrials.gov) - Oct 20, 2015
P2, N=40, Active, not recruiting, Sponsor: Janssen Research & Development, LLC
N=210 --> 1000 Recruiting --> Active, not recruiting
- ||||| New P2 trial: A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of the Combination of AL-335, Odalasvir, and Simeprevir (clinicaltrials.gov) - Oct 7, 2015
P2, N=60, Not yet recruiting, Sponsor: Alios Biopharma Inc.
- | Olysio (simeprevir) / J&J, Medivir
Trial primary completion date: Reversal of Hepatic Impairment in Patients With Hepatitis C Virus (HCV) and Early Decompensation of Cirrhosis (clinicaltrials.gov) - Oct 6, 2015
P3, N=25, Recruiting, Sponsor: University of Colorado, Denver
Recruiting --> Active, not recruiting Trial primary completion date: Aug 2015 --> Aug 2016
- | Olysio (simeprevir) / J&J, Medivir
Trial completion: A Study of Pharmacokinetics, Efficacy, Safety, Tolerability, of the Combination of Simeprevir (TMC435), Daclatasvir (BMS-790052), and Ribavirin (RBV) in Patients With Recurrent Chronic Hepatitis C Genotype 1b Infection After Orthotopic Liver Transplantation (clinicaltrials.gov) - Sep 25, 2015
P2, N=35, Completed, Sponsor: Janssen R&D Ireland
Trial primary completion date: Aug 2015 --> Aug 2016 Active, not recruiting --> Completed
- ||||||| Olysio (simeprevir) / J&J, Medivir
Trial completion: A Study of TMC435 Plus Pegylated Interferon Alfa-2a and Ribavirin in Participants With Chronic HCV Infection (clinicaltrials.gov) - Sep 25, 2015
P3, N=232, Completed, Sponsor: Janssen-Cilag International NV
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Olysio (simeprevir) / J&J, Medivir
Trial completion: A Crossover Study to Evaluate Relative Bioavailability of Simeprevir Age-appropriate Oral Formulation Candidates Compared With 150-milligram (mg) Oral Capsule in Healthy Adult Participants (clinicaltrials.gov) - Sep 24, 2015
P1, N=48, Completed, Sponsor: Janssen Sciences Ireland UC
Active, not recruiting --> Completed Recruiting --> Completed
- | Olysio (simeprevir) / J&J, Medivir
Trial initiation date: Safety, Tolerability, and Efficacy of 24 Weeks Simeprevir+Sofosbuvir for Chronic Hepatitis C Genotype 1 (clinicaltrials.gov) - Sep 17, 2015
P4, N=30, Not yet recruiting, Sponsor: Stanford University
Recruiting --> Completed Initiation date: Jun 2015 --> Oct 2015
- Olysio (simeprevir) / J&J, Medivir, Tivicay (dolutegravir) / ViiV Healthcare
Trial initiation date: Drug Interaction Potential Between Dolutegravir and Simeprevir in HIV/HCV Seronegative Volunteers (clinicaltrials.gov) - Sep 16, 2015
P=N/A, N=25, Not yet recruiting, Sponsor: University of Colorado, Denver
Initiation date: Jun 2015 --> Oct 2015 Initiation date: Jul 2015 --> Oct 2015
- Sunvepra (asunaprevir) / BMS, Olysio (simeprevir) / J&J, Medivir, Daklinza (daclatasvir) / BMS
Phase classification, Enrollment change: Triple DAAs Regimen in Treating Non-cirrhotic HCV GT1b Subjects (clinicaltrials.gov) - Aug 10, 2015
P2, N=18, Recruiting, Sponsor: Humanity & Healthy GI and Liver Centre
Initiation date: Jul 2015 --> Oct 2015 Phase classification: P4 --> P2 | N=60 --> 18
- | Olysio (simeprevir) / J&J, Medivir
Enrollment open: Reversal of Hepatic Impairment in Patients With Hepatitis C Virus (HCV) and Early Decompensation of Cirrhosis (clinicaltrials.gov) - Aug 9, 2015
P3, N=25, Recruiting, Sponsor: University of Colorado, Denver
Phase classification: P4 --> P2 | N=60 --> 18 Not yet recruiting --> Recruiting
- | New P1 trial: A Study to Evaluate the Effect of ACH-3102 and Simeprevir on AL-335 Pharmacokinetics in Healthy Volunteers (clinicaltrials.gov) - Jul 31, 2015
P1, N=32, Recruiting, Sponsor: Alios Biopharma Inc.
- || Olysio (simeprevir) / J&J, Medivir
Trial primary completion date, HEOR: A Study to Examine Patient Characteristics, Health Care Management and Health Outcomes of Hepatitis C Virus (HCV) Patients Treated With Simeprevir (clinicaltrials.gov) - Jul 20, 2015
P4, N=315, Active, not recruiting, Sponsor: Janssen Scientific Affairs, LLC
Not yet recruiting --> Recruiting Trial primary completion date: May 2016 --> Jan 2016
- Olysio (simeprevir) / J&J, Medivir
Enrollment change, Trial withdrawal: An Efficacy, Safety, Tolerability and Pharmacokinetics Study of 12 Weeks Treatment With Simeprevir and Daclatasvir in Participants With Chronic Hepatitis C Virus Genotype 1b or 4 Infection and Either Severe Renal Impairment or End-stage Renal Disease on Hemodialysis. (clinicaltrials.gov) - Jul 17, 2015
P2, N=0, Withdrawn, Sponsor: Janssen R&D Ireland
Trial primary completion date: May 2016 --> Jan 2016 N=40 --> 0 | Not yet recruiting --> Withdrawn
- Sunvepra (asunaprevir) / BMS, Olysio (simeprevir) / J&J, Medivir, Daklinza (daclatasvir) / BMS
Enrollment change: Triple DAAs Regimen in Treating Non-cirrhotic HCV GT1b Subjects (clinicaltrials.gov) - Jul 12, 2015
P4, N=60, Recruiting, Sponsor: Humanity & Healthy GI and Liver Centre
N=40 --> 0 | Not yet recruiting --> Withdrawn N=40 --> 60
- Olysio (simeprevir) / J&J, Medivir
Trial primary completion date: SMV + SOF With/Without RBV for IFN-II Patients With CHC (clinicaltrials.gov) - Jul 8, 2015
P4, N=40, Recruiting, Sponsor: SC Liver Research Consortium, LLC
N=40 --> 60 Trial primary completion date: Aug 2015 --> Jun 2016
- Olysio (simeprevir) / J&J, Medivir
New trial: Outcome of New Direct Acting Agents For Hepatitis C A Community Based Experience (clinicaltrials.gov) - Jun 30, 2015
P=N/A, N=340, Recruiting, Sponsor: Arrowhead Regional Medical Center
- | Olysio (simeprevir) / J&J, Medivir
New P4 trial: Safety, Tolerability, and Efficacy of 24 Weeks Simeprevir+Sofosbuvir for Chronic Hepatitis C Genotype 1 (clinicaltrials.gov) - Jun 30, 2015
P4, N=30, Not yet recruiting, Sponsor: Stanford University
- Olysio (simeprevir) / J&J, Medivir
Enrollment open: A Study to Investigate the Pharmacokinetic Interactions Between Simeprevir and Ledipasvir in a Treatment Regimen Consisting of Simeprevir, Sofosbuvir, and Ledipasvir in Treatment-naive Participants With Chronic Hepatitis C Virus Genotype 1 Infection (clinicaltrials.gov) - Jun 26, 2015
P2, N=40, Recruiting, Sponsor: Janssen Sciences Ireland UC
Trial primary completion date: Aug 2015 --> Jun 2016 Not yet recruiting --> Recruiting
- | Olysio (simeprevir) / J&J, Medivir
Enrollment open, Trial primary completion date, Combination therapy: Simeprevir in Combination With Sofosbuvir in Treatment-Na (clinicaltrials.gov) - Jun 23, 2015
P2, N=30, Recruiting, Sponsor: Peter J. Ruane, M.D.
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting | Trial primary completion date: May 2015 --> Jan 2016
- ||| Olysio (simeprevir) / J&J, Medivir
Enrollment closed, Enrollment change: COMMIT: A Study to Assess the Efficacy and Safety of the Combination of Simeprevir and Daclatasvir in Chronic Hepatitis C Genotype 1b-Infected Participants (clinicaltrials.gov) - Jun 20, 2015
P2, N=106, Active, not recruiting, Sponsor: Janssen-Cilag International NV
Not yet recruiting --> Recruiting | Trial primary completion date: May 2015 --> Jan 2016 Recruiting --> Active, not recruiting | N=250 --> 106
- Sunvepra (asunaprevir) / BMS, Olysio (simeprevir) / J&J, Medivir, Daklinza (daclatasvir) / BMS
New P4 trial: Triple DAAs Regimen in Treating Non-cirrhotic HCV GT1b Subjects (clinicaltrials.gov) - Jun 12, 2015
P4, N=40, Recruiting, Sponsor: Humanity & Healthy GI and Liver Centre
- Olysio (simeprevir) / J&J, Medivir, Tivicay (dolutegravir) / ViiV Healthcare
Trial initiation date: Drug Interaction Potential Between Dolutegravir and Simeprevir in HIV/HCV Seronegative Volunteers (clinicaltrials.gov) - Jun 11, 2015
P=N/A, N=25, Not yet recruiting, Sponsor: University of Colorado, Denver
Recruiting --> Active, not recruiting | N=250 --> 106 Initiation date: Apr 2015 --> Jul 2015
- ||||||| Olysio (simeprevir) / J&J, Medivir
Trial completion, Combination therapy: Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Participants With Chronic Hepatitis C Virus Infection Without Cirrhosis (clinicaltrials.gov) - Jun 6, 2015
P3, N=310, Completed, Sponsor: Janssen Infectious Diseases BVBA
Initiation date: Apr 2015 --> Jul 2015 Active, not recruiting --> Completed
- ||||||| Olysio (simeprevir) / J&J, Medivir
Trial completion, Combination therapy: Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Participants With Genotype 1 Chronic Hepatitis C Virus Infection and Cirrhosis (clinicaltrials.gov) - Jun 6, 2015
P3, N=103, Completed, Sponsor: Janssen Infectious Diseases BVBA
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||| Olysio (simeprevir) / J&J, Medivir
New P3 trial: Reversal of Hepatic Impairment in Patients With Hepatitis C Virus (HCV) and Early Decompensation of Cirrhosis (clinicaltrials.gov) - May 27, 2015
P3, N=25, Not yet recruiting, Sponsor: University of Colorado, Denver
- Olysio (simeprevir) / J&J, Medivir
Enrollment open: A Crossover Study to Evaluate Relative Bioavailability of Simeprevir Age-appropriate Oral Formulation Candidates Compared With 150-milligram (mg) Oral Capsule in Healthy Adult Participants (clinicaltrials.gov) - May 27, 2015
P1, N=48, Recruiting, Sponsor: Janssen Sciences Ireland UC
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- | Olysio (simeprevir) / J&J, Medivir
Enrollment closed: An Efficacy and Safety Study of Simeprevir and Sofosbuvir With and Without Ribavirin in Participants With Recurrent Genotype 1 Hepatitis C Post-Orthotopic Liver Transplant (clinicaltrials.gov) - May 21, 2015
P2, N=46, Active, not recruiting, Sponsor: Janssen Scientific Affairs, LLC
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- ||| Olysio (simeprevir) / J&J, Medivir
Enrollment closed, HEOR: A Study to Examine Patient Characteristics, Health Care Management and Health Outcomes of Hepatitis C Virus (HCV) Patients Treated With Simeprevir (clinicaltrials.gov) - May 8, 2015
P4, N=314, Active, not recruiting, Sponsor: Janssen Scientific Affairs, LLC
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- | Olysio (simeprevir) / J&J, Medivir
Enrollment closed, Combination therapy: Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Subjects With Chronic Genotype 4 Hepatitis C Virus Infection (clinicaltrials.gov) - Apr 25, 2015
P3, N=41, Active, not recruiting, Sponsor: Janssen R&D Ireland
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- |||| samatasvir (IDX719) / Merck (MSD)
Trial completion: Samatasvir (IDX719) in Combinations With Simeprevir and/or TMC647055/Ritonavir With or Without Ribavirin for 12 Weeks in Participants With Chronic Hepatitis C Infection (MK-1894-005) (clinicaltrials.gov) - Apr 23, 2015
P2, N=143, Completed, Sponsor: Merck Sharp & Dohme Corp.
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Olysio (simeprevir) / J&J, Medivir
New P2 trial: A Study to Investigate the Pharmacokinetic Interactions Between Simeprevir and Ledipasvir in a Treatment Regimen Consisting of Simeprevir, Sofosbuvir, and Ledipasvir in Treatment-naive Participants With Chronic Hepatitis C Virus Genotype 1 Infection (clinicaltrials.gov) - Apr 20, 2015
P2, N=40, Not yet recruiting, Sponsor: Janssen Sciences Ireland UC
- ||||||| Olysio (simeprevir) / J&J, Medivir
Trial completion, Combination therapy: A Study of TMC435 in Combination With Peginterferon Alfa-2A and Ribavirin for Hepatitis C Virus Genotype-1 Infected Patients Who Participated in a Control Group of a TMC435 Study (clinicaltrials.gov) - Apr 8, 2015
P3, N=142, Completed, Sponsor: Janssen R&D Ireland
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Olysio (simeprevir) / J&J, Medivir, Tivicay (dolutegravir) / ViiV Healthcare
New trial: Drug Interaction Potential Between Dolutegravir and Simeprevir in HIV/HCV Seronegative Volunteers (clinicaltrials.gov) - Apr 2, 2015
P=N/A, N=25, Not yet recruiting, Sponsor: University of Colorado, Denver
- | Olysio (simeprevir) / J&J, Medivir
New P2 trial: An Efficacy, Safety, Tolerability and Pharmacokinetics Study of 12 Weeks Treatment With Simeprevir and Daclatasvir in Participants With Chronic Hepatitis C Virus Genotype 1b or 4 Infection and Either Severe Renal Impairment or End-stage Renal Disease on Hemodialysis. (clinicaltrials.gov) - Mar 26, 2015
P2, N=40, Not yet recruiting, Sponsor: Janssen R&D Ireland
- Olysio (simeprevir) / J&J, Medivir
New P1 trial: A Crossover Study to Evaluate Relative Bioavailability of Simeprevir Age-appropriate Oral Formulation Candidates Compared With 150-milligram (mg) Oral Capsule in Healthy Adult Participants (clinicaltrials.gov) - Mar 11, 2015
P1, N=48, Not yet recruiting, Sponsor: Janssen Sciences Ireland UC